Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data Full Text
Therapeutics and Clinical Risk Management, 06/26/2012
Bloomgren G et al. – Results from this evaluation provide no evidence of an increased risk of malignancy with intramuscular IFN(beta)–1a use.
